Last reviewed · How we verify
NCT04438681: INSTIGO
Evaluation of a Plasma Protein Profile as a Predictive Biomarker for Metastatic Relapse in Triple Negative Breast Cancer Patients
trial in Triple Negative Breast Cancer in 90 participants. Participants enrolled and being followed up; not accepting new ones.
9 November 2026
Quick facts
| Lead sponsor | Centre Jean Perrin |
|---|---|
| Status | Active, enrolled |
| Study type | OBSERVATIONAL |
| Enrollment | 90 |
| Start date | 27 November 2020 |
| Primary completion | 9 November 2026 |
| Estimated completion | 9 November 2029 |
| Sites | 1 location across France |
Conditions studied
- Triple Negative Breast Cancer — all drugs for Triple Negative Breast Cancer →
Sponsor
Centre Jean Perrin — full company profile →
Who can join
18 and older, female only, with Triple Negative Breast Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The INSTIGO study aims to assess a plasma protein profile at different stages of patient follow-up as a predictive factor of metastatic recurrence in triple negative breast cancer. It also aims to look at other potential biomarkers of metastatic relapse such as Tumor-infiltrating Lymphocytes, circulating tumor DNA, figurative elements in blood, or a tumor RNA signature.
Publications & conference data
3 peer-reviewed publications reference this trial (live from Europe PMC):
-
Circulating proteins as predictive and prognostic biomarkers in breast cancer.
Veyssière H, Bidet Y, Penault-Llorca F, Radosevic-Robin N, et al · · 2022 · cited 42× · PMID 35818030 · DOI 10.1186/s12014-022-09362-0 -
INSTIGO Trial: Evaluation of a Plasma Protein Profile as a Predictive Biomarker for Metastatic Relapse of Triple Negative Breast Cancer.
Veyssière H, Lusho S, Molnar I, Kossai M, et al · · 2021 · cited 6× · PMID 34249690 · DOI 10.3389/fonc.2021.653370 -
Identification of serum proteins associated with response of triple-negative breast cancer to neoadjuvant chemotherapy: preliminary results from the INSTIGO trial.
Pinard C, Ginzac A, Molnar I, Veyssiere H, et al · · 2025 · PMID 41462069 · DOI 10.1186/s12014-025-09574-0
Verify or expand the search:
- PubMed search for NCT04438681
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Triple Negative Breast Cancer
Currently open trials in the same condition.
- NCT07533123 — A Phase III Study of JSKN016 Versus Treatment of Physician's Choice in Patients With Triple-Negative Breast Cancer Who H · Phase 3 · recruiting
- NCT07503808 — A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types · Phase 1 · recruiting
- NCT07340541 — Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies · Phase 2 · recruiting
- NCT07281976 — A Trial of LBL-024 Monotherapy or Combination Drug in Patients With Triple Negative Breast Cancer · Phase 1, PHASE2 · recruiting
- NCT06225505 — Early Detection of Triple Negative Breast Cancer Relapse (CUPCAKE) · NA · recruiting
Other Centre Jean Perrin trials
Trials by the same sponsor.
- NCT07361471 — Identification of Genetic, Phenotypic, Clinical, Biological and Histological Factors Differentiating Patients With Ovari · NA · recruiting
- NCT06512558 — Augmented Reality Feasibility for Non-invasive Preoperative Tracking in Breast Cancer Surgery · NA · recruiting
- NCT06600802 — Intrinsic Validity of Molecular Marker(s) Detection on Tissular Tumoral DNA to Predict the Efficacy of 177Lutetium-PSMA- · NA · recruiting
- NCT05433077 — Support and Post-therapeutic Rehabilitation for Women in Complete Remission of Breast Cancer in a Thermal Environment · active not recruiting
- NCT05157594 — hPG80 (Circulating Progastrin) as a Blood Biomarker for High-grade Glial Tumors · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04438681 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Centre Jean Perrin
- Last refreshed: 4 December 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04438681.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing